Omnadren 250 human intermediate-acting insulin, produced by recombinant biotechnology using a strain of Saccharomyces cerevisiae. Interacts with the specific receptor of the outer plasma membrane of cells to form insulin-receptor complex stimulates intracellular processes, in Vol. H. The synthesis of a number of key enzymes (hexokinase, pyruvate kinase, glycogen, etc.).
The decrease in blood glucose due to an increase of intracellular transport, enhanced assimilation tissue, stimulation of lipogenesis, glikogenogeneza, speed reduction glucose production by the liver, and others.
The duration of action of insulin formulations is mainly due to absorption rate, which depends on several factors (e.g., dose, method, site of administration and type diabetes), therefore the action profile insulin fluctuate significantly, like different people, and at one and the same person. Its action begins for 1 1/2 hours after the administration, and the maximum effect is apparent within 4-12 hours, the total duration is about 24 hours.
Weight insulin absorption and onset of the effect depends on the method of administration (subcutaneous, intramuscular ), injection site (abdomen, thigh, buttocks), the dose (volume of insulin), insulin concentration in the preparation:., etc. The maximum concentration in plasma insulin is attained within 2-18 hours after subcutaneous administration. Distribution Pronounced binding with plasma proteins is not observed, sometimes only detected circulating antibodies to insulin. Metabolism Human insulin is cleaved by the protease insulin or insulin-degrading enzymes and possibly under the action of a protein disulfide isomerase. It is assumed that in the human insulin molecule has multiple cleavage sites (hydrolysis); However, none of the metabolites formed due to splitting, is not active. Elimination half-life (T1 / 2) is determined by the rate of absorption from subcutaneous tissues. Thus, T1 / 2 is more a measure of absorption, but not actually measure insulin clearance from the plasma (T1 / 2 of insulin from the bloodstream is equal to only a few minutes). Studies have shown that the T1 / 2 is about 5-10 hours.
Preclinical safety data During preclinical studies, including toxicity studies with repeated administration of doses, genotoxicity studies of the carcinogenic potential and toxicity to the reproductive sphere, specific risk of human d.lya It has been omnadren 250 identified.
Hypersensitivity to human insulin or to any component that is part of the drug.
Pregnancy and lactation
are no restrictions on the use of insulin during pregnancy does not exist, because insulin does not cross the placental barrier. Moreover, if you do not carry out the treatment of diabetes during pregnancy, it created a risk to the fetus. Therefore diabetes therapy should be continued and during pregnancy.
As hypoglycaemia and hyperglycaemia, which can develop in cases not accurately matched therapies increase the risk of fetal malformations and fetal death. Pregnant women with diabetes during pregnancy should be monitored, they need to exercise greater control of blood glucose levels; the same recommendations also apply to women who are planning a pregnancy.
Insulin requirements are usually reduced in the first trimester of pregnancy and is gradually increased in the second and third trimesters.
After delivery, insulin requirements quickly returns to a level that was observed prior to pregnancy.
There are also omnadren 250 no restrictions use of the drug lactation. Carrying insulipoterapii nursing mothers is not dangerous for the baby. However, the mother may require correction dosing regimen medication and / or diet.